| A2652 |
Sibrotuzumab (Anti-FAP) |
Sibrotuzumab (Anti-FAP) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). It can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC). MW :148.66 KD. |
Human IgG1 |
| A2908 |
Anti-DDR1 / CD167a (Imperial College anti-DDR1) |
Anti-DDR1 / CD167a (Imperial College anti-DDR1) is a monoclonal antibody againts discoidin domain receptor 1 with potential anti-tumor activity. MW: 143.32 KD. |
Human IgG1 |
| A3164 |
Serclutamab (Anti-ERBB1 / EGFR / HER1) |
Serclutamab (Anti-ERBB1 / EGFR / HER1) is a monoclonal antibody targeting epidermal growth factor receptor (EGFR). It can be used in research of advanced solid tumors for advanced glioblastoma. MW :150 KD. |
Human IgG1 |
| A2653 |
Anti-FGF19 (1A6) |
Anti-FGF19 (1A6) is a humanized monoclonal antibody that specifically targets FGF19. It has antitumoe activities and can used in the treatment of hepatocellular carcinoma (HCC). MW :145.2 KD. |
Human IgG1 |
| A2909 |
Anti-FGFR1 / CD331 |
Anti-FGFR1 / CD331 is a monoclonal antibody againts human fibroblast growth factor receptor 1. MW: 150 KD. |
Human IgG1 |
| A3165 |
Anti-TfR (Jr-141) |
Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD. |
Human IgG1 |
| A2654 |
Anti-Fibronectin (L19-TNF) |
Anti-Fibronectin (L19-TNF) is a monoclonal antibody targeting fibronectin ED-B and interleukin 12. it can be used in treatment of advanced soft-tissue sarcoma. MW :144.14 KD. |
Human IgG4SP |
| A2910 |
Anti-TSPAN8 |
Anti-TSPAN8 is a monoclonal IgG1 antibody (mAb) directed against Co-029, a membrane protein of the family of tetraspanins (TSPAN8 or TM4SF3). MW: 145.94 KD. |
Human IgG1 |
| A3166 |
Anti-MSPR / RON / CD136 (H5B14) |
Anti-MSPR / RON / CD136 (H5B14) is a neutralizing human monoclonal antibody-drug conjugate that targets RON binding to its ligand, macrophage-stimulating protein (MSP). It has an strong potential in treatment of chronic liver inflammation and also in autoimmune diseases. MW :156.7 KD. |
Human IgG1 |
| A2655 |
Crotedumab (Anti-GCGR) |
Crotedumab (Anti-GCGR) is a fully human IgG4 monoclonal antibody targeting glucagon receptor (GCGR). It can be used for the research of diabetes. MW :146.98 KD. |
Human IgG4SP |
| A2911 |
Radretumab (Anti-Fibronectin) |
Radretumab (anti-fibronectin) is a monoclonal antibody that targets the extra-domain B fibronectin present in the extracellular matrix surrounding newly formed blood vessels in solid tumors. MW: 144.2 KD. |
Human IgG1 |
| A3167 |
Anti-PVR / CD155 (Ntx1088) |
Anti-PVR / CD155 (Ntx1088) is a first-in-class potent monoclonal antibody targeting poliovirus receptor. It can be used in treatment of patients with locally advanced and metastatic solid tumors. MW :145.86 KD. |
Human IgG1 |
| A2656 |
Anti-CSF3R / G-CSFR |
Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD. |
Human IgG4SP |
| A2912 |
Pelgifatamab (Anti-FOLH1 / PSMA) |
Pelgifatamab (anti-FOLH1 / PSMA) is an immunoglobulin G1-kappa monoclonal antibody targated against FOLH1 (folate hydrolase, prostate-specific membrane antigen, psma). MW: 146.24 KD. |
Human IgG1 |
| A3168 |
Anti-CD98 (Ign523) |
Anti-CD98 (Ign523) is a humanized monoclonal antibody targeting CD98. It can be used in patients with relapsed or refractory acute myeloid leukemia (AML). MW :145.66 KD. |
Human IgG1 |
| A2657 |
Anti-GPR49 / LGR5 (BNC101) |
Anti-GPR49 / LGR5 (BNC101) is a human specific monoclonal antibody targeting the GPCR-LGR5. It can be used in the treatment of metastatic colorectal cancer (CRC). MW :150 KD. |
Human IgG1 |
| A2913 |
Iparomlimab (Anti-PDCD1 / PD-1 / CD279) |
Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD. |
Human IgG4SP |
| A3169 |
Anti-TREM2 (Py314) |
Anti-TREM2 (Py314) is a humanized monoclonal antibody that specifically targets the triggering receptor expressed on myeloid cells 2 (TREM2). It can be used in cancer research and in treatment of variety of solid tumor types. MW :145.24 KD. |
Human IgG1 |
| A2914 |
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) |
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD. |
Human IgG2SA |
| A3170 |
Tidutamab (Anti-CD3 & SSTR2) |
Tidutamab (Anti-CD3 & SSTR2) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). It can be used in neuroendocrine tumors (NETs) and small cell lung cancer (SCLC). MW :147.36 KD. |
Human IgG1 |